10x Genomics announced its involvement in TenK10K, a large-scale, multi-year study led by the Garvan Institute of Medical Research. The TenK10K project intends to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer. For this groundbreaking project, the Garvan Institute selected Chromium GEM-X products to generate single cell data to improve the accuracy of predicting disease risk and treatment response. As part of this new study, the Garvan Institute will use Chromium GEM-X products, the next generation of 10x Genomics’ leading single cell technology, delivering increased sensitivity, throughput, data quality and sample recovery. GEM-X is uniquely positioned for translational research, delivering class-leading performance at larger scale and lower cost, even with more challenging samples.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Cathie Wood’s ARK Investment buys 392.5K shares of 10x Genomics today
- Cathie Wood’s ARK Investment buys 122K shares of 10x Genomics today
- 10x Genomics price target lowered to $32 from $50 at Canaccord
- Cathie Wood’s ARK Investment buys 144K shares of 10x Genomics today
- 10x Genomics upgraded to Buy from Hold at Jefferies
Questions or Comments about the article? Write to editor@tipranks.com